PTX 0.00% 3.9¢ prescient therapeutics limited

Ann: Encouraging data from PTX-200 ovarian cancer trial, page-53

  1. 915 Posts.
    lightbulb Created with Sketch. 26
    When the likes of CS jumped in as a substantial holder, the results are proving better than what’s currently available on the market for patients, and the buy outs that have occurred over the past year. How can you not be happy?
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.